EP 027315
Alternative Names: EP-027315Latest Information Update: 28 May 2023
At a glance
- Originator Enanta Pharmaceuticals
- Class Anti-inflammatories; Hepatoprotectants; Small molecules
- Mechanism of Action MAP-kinase-activated kinase 5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Liver disorders; Metabolic disorders